Molecular therapy for Diabetic nephropathy (DN): Atorvastatin (trade name: Lipitor), a lipid-lowering medication, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 15/November/2017, 5.38 am
Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.” This research paper was published, in the 24 April 2017 issue of the journal “Nature Medicine” [One of the best research journals in “Molecular […]
Natural product-derived therapy for Diabetic Kidney disease: Methyl Jasmonate (MeJA), isolated from Jasmine, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene, 23/June/2017, 9.39 am
Introduction: What they say A study from the Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden shows that “Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.” This research paper was published in the 9 February 2017 issue of the journal “Cell Metabolism” [One […]